Kronos Bio Inc (NAS:KRON)

$ 1.0011 -0.0089 (-0.88%) Market Cap: 60.16 Mil Enterprise Value: -63.81 Mil PE Ratio: 0 PB Ratio: 0.44 GF Score: 32/100

Kronos Bio Inc Phase 1/2 KB-0742 Data Update Call Transcript
Oct 13, 2023
Kronos Bio Inc Annual Shareholders Meeting Transcript
Jun 22, 2023
Kronos Bio Inc at Goldman Sachs Healthcare Conference Transcript
Jun 15, 2023
Kronos Bio Inc at Jefferies Healthcare Conference Transcript
Jun 08, 2023
Kronos Bio Inc at Cowen Health Care Conference Transcript
Mar 07, 2023
Kronos Bio Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript
Dec 01, 2022
Kronos Bio Inc at Piper Sandler Healthcare Conference Transcript
Nov 29, 2022
Kronos Bio Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Sep 12, 2022
Kronos Bio Inc at Goldman Sachs Global Healthcare Conference Transcript
Jun 15, 2022
Kronos Bio Inc Annual Shareholders Meeting Transcript
Jun 22, 2021
Kronos Bio Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 09, 2021
Kronos Bio Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript
May 13, 2021

Kronos Bio Inc at Cowen Health Care Conference Transcript

Mar 07, 2023 / 02:10PM GMT

Release Date Price: $1.72 (-2.82%)

Transcript 10-K8-K

Tyler Van Buren

Cowen Inc. - Analyst

[Good morning, everyone]. Welcome again to the second day of TD Cowen's 43rd Annual Health Care Conference. For this next corporate panel, we're very pleased to be discussing novel oncology targets. My name is Tyler Van Buren, senior biotech analyst at TD Cowen. I'm also joined by my colleagues, Boris Peaker, Anvita Gupta, and Eva Privitera.

And then from the companies, we're very pleased to have six companies with us. We have John Orwin, President and CEO of Atreca; Sean McCarthy, CEO and Chairman of CytomX; John Valliant, Chief Executive Officer of Fusion Pharmaceuticals; Norbert Bischofberger, President and CEO of Kronos Bio; David Woodhouse, CEO of NGM Biopharmaceuticals; and Nancy Simonian, President and CEO of Syros Pharmaceuticals.

So the plan is to start with some thematic questions that will be a free for all, open to anyone who wants to comment, and I will get into some company-specific questions. (Conference Instructions)

Questions & Answers

Tyler Van Buren

Cowen Inc. - Analyst

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.